“Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data”. 2018. SKIN The Journal of Cutaneous Medicine 2 (December): S78. https://doi.org/10.25251/skin.2.supp.78.